Selected article for: "vaccine development and viral vector"

Author: Kochhar, Sonali; Kim, Denny; Excler, Jean-Louis; Condit, Richard C.; Robertson, James S.; Drew, Stephen; Whelan, Mike; Wood, David; Fast, Patricia E.; Gurwith, Marc; Klug, Bettina; Khuri-Bulos, Najwa; Smith, Emily R.; Chen, Robert T
Title: The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
  • Cord-id: bn665yfr
  • Document date: 2020_7_9
  • ID: bn665yfr
    Snippet: Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help cont
    Document: Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.

    Search related documents:
    Co phrase search for related documents
    • ade antibody dependent enhancement and live virus: 1, 2, 3
    • administration delivery and live virus: 1, 2